Effect of tenofovir subtraction on HIV plasma viraemia, CD4+ T-cell count and resistance in a patient with baseline K65R and M184V mutations
| Autor: | Ernest R Lanier, Elizabeth G Rouse, Lisa Ross, Ricky Hsu, Katrina L Oie, Keith A. Pappa |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Pharmacology
Mutation Reverse-transcriptase inhibitor viruses virus diseases Viremia biochemical phenomena metabolism and nutrition Biology Resistance mutation medicine.disease medicine.disease_cause biology.organism_classification Virology Reverse transcriptase Virus Infectious Diseases Acquired immunodeficiency syndrome (AIDS) immune system diseases Lentivirus medicine Pharmacology (medical) medicine.drug |
| Zdroj: | Antiviral Therapy. 13:735-737 |
| ISSN: | 2040-2058 1359-6535 |
| Popis: | In vitro, the reverse transcriptase mutation K65R can simultaneously reduce drug susceptibility, replicative capacity and restrict HIV-1 replication. Here, we assessed the effect of tenofovir discontinuation for a patient receiving antiretroviral therapy whose HIV-1 had a dominant K65R/M184V genotype. Although limited by the single-case nature, the data support a hypothesis that there is no HIV viral RNA or CD4+ T-cell count benefit of taking tenofovir for experienced patients with genotypic evidence of K65R/M184V. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|